Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Viridian Therapeutics Inc’s stock clocked out at $12.88, up 1.42% from its previous closing price of $12.70. In other words, the price has increased by $1.42 from its previous closing price. On the day, 0.54 million shares were traded. VRDN stock price reached its highest trading level at $13.06 during the session, while it also had its lowest trading level at $12.43.
Ratios:
To gain a deeper understanding of VRDN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.26 and its Current Ratio is at 18.26. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On June 14, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $46.
On May 30, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $44.RBC Capital Mkts initiated its Outperform rating on May 30, 2023, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 22 ’24 when Fairmount Funds Management LLC bought 476,190 shares for $21.00 per share. The transaction valued at 9,999,990 led to the insider holds 1,839,954 shares of the business.
Meisner Lara sold 27 shares of VRDN for $765 on Jun 16 ’23. The Chief Legal Officer now owns 29,971 shares after completing the transaction at $28.35 per share. On Jun 15 ’23, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 2,269 shares for $28.02 each. As a result, the insider received 63,577 and left with 29,971 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 808446720 and an Enterprise Value of 559629312. For the stock, the TTM Price-to-Sale (P/S) ratio is 2607.99 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 1782.259 whereas that against EBITDA is -2.204.
Stock Price History:
The Beta on a monthly basis for VRDN is 1.17, which has changed by -0.5502793 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $28.99, while it has fallen to a 52-week low of $10.93. The 50-Day Moving Average of the stock is -25.64%, while the 200-Day Moving Average is calculated to be -27.09%.
Shares Statistics:
It appears that VRDN traded 900.05K shares on average per day over the past three months and 791210 shares per day over the past ten days. A total of 62.77M shares are outstanding, with a floating share count of 55.85M. Insiders hold about 11.02% of the company’s shares, while institutions hold 90.22% stake in the company. Shares short for VRDN as of 1713139200 were 9726768 with a Short Ratio of 10.81, compared to 1710460800 on 7619785. Therefore, it implies a Short% of Shares Outstanding of 9726768 and a Short% of Float of 15.840000000000002.
Earnings Estimates
Current recommendations for the stock of the company come from 12.0 analysts. On average, analysts expect EPS of -$1.1 for the current quarter, with a high estimate of -$0.81 and a low estimate of -$1.36, while EPS last year was -$1.61. The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.84 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$3.44 and -$5.72 for the fiscal current year, implying an average EPS of -$4.54. EPS for the following year is -$4.57, with 12.0 analysts recommending between -$3.23 and -$6.69.
